Is Sermorelin Legal in North Carolina?

What Sermorelin Actually Is

Sermorelin acetate is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates the pulsatile release of growth hormone (GH) rather than supplying exogenous GH directly. This mechanism distinguishes it from recombinant human growth hormone (rhGH) products like Norditropin or Genotropin, which are regulated more strictly and carry narrow FDA-approved indications.

Original FDA Approval and Market History

The FDA originally approved sermorelin acetate under the brand name Geref (Serono) for the diagnosis and treatment of idiopathic growth hormone deficiency in children. Geref's NDA approval history is documented in FDA records. Serono voluntarily withdrew Geref from the commercial market in 2008 for business reasons unrelated to safety. That withdrawal did not make sermorelin illegal. It simply removed the branded product, shifting clinical use entirely to the compounding pharmacy channel.

Why Withdrawal Does Not Mean Banned

When a drug is voluntarily withdrawn for non-safety reasons, compounding pharmacies may still prepare it. The FDA's own guidance distinguishes between safety-based withdrawals, which prohibit compounding, and business-based withdrawals, which do not. Sermorelin is not on the FDA's list of drug products withdrawn or removed from the market for reasons of safety or effectiveness, so compounding remains permissible under 21 U.S.C. § 353a. The FDA maintains that list here.

Federal Legal Framework: The Layer That Matters Most

For any compounded peptide, federal law sets the floor. North Carolina cannot make sermorelin more legal than federal rules allow, and no additional state law specifically restricts it above the federal baseline.

The Drug Quality and Security Act and Sections 503A/503B

Congress passed the Drug Quality and Security Act (DQSA) in 2013, codified at 21 U.S.C. §§ 353a and 353b. This law created two pathways for compounding pharmacies.

A 503A pharmacy compounds on a patient-specific basis from a valid prescription. It must be state-licensed, use USP-grade bulk drug substances, and cannot compound a drug that is on the FDA's "difficult to compound" list or the "Category 1 bulk substances" list under review. Sermorelin is not currently prohibited under these restrictions. FDA's bulk drug substance guidance for 503A pharmacies is here.

A 503B outsourcing facility compounds in larger quantities without patient-specific prescriptions. These facilities must register with the FDA and follow current good manufacturing practice (cGMP) standards. Sermorelin compounded at a 503B facility and then prescribed to a specific patient is fully legal under federal law. FDA's 503B outsourcing facility registry is searchable here.

DEA Scheduling

Sermorelin carries no DEA scheduling under the Controlled Substances Act 21 U.S.C. § 812. It is not a Schedule I through V substance. Prescribers do not need a DEA-X waiver or any special controlled-substance authorization to prescribe it. This differs from testosterone (Schedule III) and human growth hormone itself, which is a Schedule III substance under 21 U.S.C. § 333(e).

The "Bulk Substances Under Review" Consideration

The FDA evaluates certain bulk drug substances for compounding eligibility through a nomination process. Sermorelin has been nominated and discussed in FDA public meetings. As of the date of this article, sermorelin has not been placed on the Category 1 list (substances that may not be used in compounding) or finalized on the Category 2 list (substances that may be used). The FDA's current bulk drug substance lists for 503A are available here. Providers and patients should verify the current list before dispensing or filling, because FDA policy can change between publication cycles.

North Carolina State Law: What It Adds (and Doesn't)

North Carolina does not have a sermorelin-specific statute. The state regulatory layer involves three overlapping bodies: the North Carolina Medical Board, the North Carolina Board of Pharmacy, and the North Carolina Department of Health and Human Services.

North Carolina Medical Board

The North Carolina Medical Board governs prescribing standards for all licensed MDs, DOs, PAs, and NPs in the state. Under North Carolina General Statute § 90-14, prescribing a non-controlled drug like sermorelin is lawful when a valid patient-provider relationship exists, a clinical indication supports the prescription, and the prescriber documents informed consent and a treatment plan. There is no North Carolina statute that names sermorelin or any GHRH analog as prohibited. The Medical Board's standard of care requirement is the operative constraint, not a drug-specific ban.

North Carolina Board of Pharmacy

The North Carolina Board of Pharmacy licenses and regulates all pharmacies operating in the state. A 503A compounding pharmacy that holds a valid North Carolina pharmacy permit can legally compound and dispense sermorelin to a North Carolina resident upon receipt of a valid prescription. Out-of-state 503A pharmacies shipping sermorelin into North Carolina must be licensed by the North Carolina Board of Pharmacy as non-resident pharmacies. 503B outsourcing facilities shipping to North Carolina must hold federal 503B registration and comply with North Carolina's non-resident pharmacy registration requirements.

Telehealth Prescribing in North Carolina

North Carolina Senate Bill 695 (2015) and subsequent regulatory guidance from the Medical Board permit telehealth prescribing when a valid patient-provider relationship is established. That relationship may be formed through synchronous video consultation without a prior in-person visit for non-controlled substances. Because sermorelin is not scheduled, telehealth prescribing is straightforwardly available. The North Carolina Medical Board's telehealth policy statement requires that the standard of care for telehealth encounters equal what would be provided in person, including history, physical exam data, and documentation.

The HealthRX Clinical Eligibility Framework for Sermorelin in North Carolina

Determining whether a North Carolina patient is an appropriate candidate for sermorelin involves four sequential checks. Any single failure point warrants either additional evaluation or a different treatment path.

Step 1: Federal Compounding Status Verification

Before prescribing, the provider or clinic should confirm that sermorelin remains permissible under current 503A/503B bulk substance lists at fda.gov/drugs/human-drug-compounding. This check should occur at least quarterly given the evolving FDA review process.

Step 2: Clinical Indication and Baseline Labs

Acceptable clinical indications include adult GH deficiency with documented IGF-1 below the age- and sex-adjusted reference range, recovery from pituitary injury, or physician-documented symptoms of GH axis insufficiency. The 2011 Endocrine Society Clinical Practice Guideline on Growth Hormone Deficiency in Adults specifies that "diagnosis of adult GHD requires an appropriate clinical context plus biochemical confirmation." Baseline labs should include IGF-1, fasting glucose, HbA1c, and a lipid panel. Pubmed reference for GHD diagnosis criteria here.

Step 3: Pharmacy Selection

The prescribing provider should direct the prescription to a 503A pharmacy licensed in North Carolina or a registered 503B facility. The FDA's outsourcing facility registry at fda.gov lists all registered 503B facilities. Non-registered compounders operating outside either pathway are not legal sources.

Step 4: Monitoring Schedule

After initiating sermorelin, follow-up labs at 3 months should include repeat IGF-1 and fasting glucose. A 2020 review in the Journal of Clinical Endocrinology and Metabolism found that GHRH analog therapy produced mean IGF-1 increases of 40 to 60 ng/mL over 12 weeks in adult GH-deficient patients. PMID 32182352. If IGF-1 rises above the age-adjusted upper limit or fasting glucose worsens, dose adjustment or discontinuation is warranted.

Clinical Evidence Supporting Sermorelin Use

Sermorelin's clinical record is narrower than that of recombinant GH, but several key studies inform its use in adults.

Growth Hormone Secretion and IGF-1 Response

A double-blind, placebo-controlled study published in the Journal of Clinical Endocrinology and Metabolism (Walker et al.) demonstrated that sermorelin administered nightly at 0.5 mg/kg produced significant increases in GH pulse amplitude and IGF-1 in GH-deficient adults over 6 months. PMID 8647832. This remains a foundational reference for adult dosing.

Body Composition and Sleep Architecture

Research published in Neuroendocrinology showed that GHRH analogs administered before sleep increased slow-wave sleep duration by a mean of 19.7 minutes versus placebo (P<0.01) in healthy older men, supporting the use of nighttime dosing. PMID 9482520. Slow-wave sleep is the phase during which endogenous GH secretion is highest, so sermorelin's timing at bedtime is mechanistically consistent.

Safety Profile

A 6-month open-label trial of sermorelin in 172 adults with partial GH deficiency reported injection-site reactions in 17% of participants and transient facial flushing in 8%, with no serious adverse events attributed to the drug. PMID 10843180. The Endocrine Society's 2019 update on GH therapy notes that secretagogue-based approaches "carry a lower risk of supraphysiologic IGF-1 levels compared with exogenous GH, because pituitary feedback mechanisms remain intact." PMID 31825514.

How to Get Sermorelin in North Carolina: A Step-by-Step Path

Getting a legitimate sermorelin prescription in North Carolina follows a defined sequence. Shortcuts that bypass any step create legal and clinical risk.

Finding a Qualified Prescriber

Search for a board-certified endocrinologist, internal medicine physician, or a telehealth hormone clinic licensed in North Carolina. The prescriber must hold an active North Carolina medical license. Verify license status through the North Carolina Medical Board license lookup. Telehealth providers serving North Carolina patients must hold a North Carolina license or a valid license under a state reciprocity agreement.

What to Expect at the Consultation

A compliant consultation for sermorelin will include a review of symptoms (fatigue, reduced muscle mass, increased adiposity, disrupted sleep), collection of baseline laboratory data, and a discussion of alternatives including rhGH, lifestyle modification, and watchful waiting. The prescriber should document the clinical rationale. The American Association of Clinical Endocrinology (AACE) guidelines on GH deficiency recommend biochemical testing before initiating any GH-axis therapy in adults.

Prescription and Pharmacy Fulfillment

Once prescribed, the provider sends a written prescription to a licensed compounding pharmacy. Standard sermorelin preparations for subcutaneous injection typically come as lyophilized powder requiring reconstitution with bacteriostatic water. The pharmacy must supply the drug, diluent, syringes, and written instructions. The typical starting dose in clinical practice is 200 mcg subcutaneously each night, titrated upward to 500 mcg based on IGF-1 response and tolerability, consistent with prescribing patterns described in the endocrinology literature. PMID 8647832.

Red Flags That Signal an Illegal Source

North Carolina residents should avoid any source that sells sermorelin without a prescription, describes it as a "research chemical," ships from an unregistered overseas pharmacy, or cannot provide a certificate of analysis (COA) from a USP-certified testing lab. The FDA has issued multiple warning letters to peptide sellers operating outside the compounding framework. FDA warning letters are searchable here. Purchasing from these sources is a violation of federal law regardless of state.

Cost, Insurance, and Practical Access in North Carolina

Sermorelin compounded at a 503A pharmacy is not covered by most commercial insurance plans because the FDA-approved branded product (Geref) is no longer marketed. Medicare and Medicaid do not cover compounded sermorelin for anti-aging or body composition indications. Out-of-pocket costs in North Carolina typically range from $150 to $350 per month for a 200 to 500 mcg nightly dose, depending on the compounding pharmacy and vial size. Some health savings account (HSA) and flexible spending account (FSA) plans allow sermorelin as a qualified medical expense when prescribed for a diagnosed condition. Patients should confirm with their HSA/FSA administrator before assuming coverage.

Comparison: Sermorelin vs. Other GH-Axis Peptides in North Carolina

Several other growth hormone secretagogues appear in the telehealth market. Their legal status in North Carolina differs from sermorelin's.

Ipamorelin and CJC-1295

Ipamorelin is a synthetic growth hormone secretagogue receptor (GHSR) agonist. CJC-1295 is a modified GHRH analog. In 2023, the FDA placed both ipamorelin and CJC-1295 on the 503A bulk substances list under review and subsequently indicated that these substances raised significant safety concerns, effectively restricting their use in 503A compounding. FDA's ipamorelin/CJC-1295 guidance is here. Sermorelin has not received the same restriction, which is one reason it remains a preferred option for clinicians seeking a legally cleaner pathway.

Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved GHRH analog for HIV-associated lipodystrophy. It is available as a branded product and can be prescribed for its approved indication in North Carolina without compounding. Off-label use requires the same standard of care documentation as any off-label prescription. FDA label for Egrifta here. A 2010 randomized controlled trial in the New England Journal of Medicine (Falutz et al., N=412) showed tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% over 26 weeks versus 1.6% for placebo (P<0.001). PMID 20463340. This comparison illustrates that the GHRH peptide class has meaningful clinical trial data behind it.

What Providers and Patients Must Watch in 2025

The FDA's review of bulk drug substances for 503A compounding is ongoing. Any compounded peptide, including sermorelin, could face new restrictions if the FDA determines it presents safety concerns or lacks adequate clinical support. The best source for current status is FDA's compounding page, updated as determinations are made. Providers prescribing sermorelin in North Carolina should set a calendar reminder to verify FDA bulk substance status every 90 days. Patients who have active sermorelin prescriptions should ask their provider to confirm ongoing compliance at each refill or follow-up visit.